{"id":5777,"date":"2022-12-21T11:28:26","date_gmt":"2022-12-21T17:28:26","guid":{"rendered":"http:\/\/antiagecr.com\/?page_id=5777"},"modified":"2022-12-27T20:20:29","modified_gmt":"2022-12-28T02:20:29","slug":"mounjaro-tirzepatide","status":"publish","type":"post","link":"https:\/\/antiagecr.com\/es\/mounjaro-tirzepatide\/","title":{"rendered":"Mounjaro Tirzepatide Diabetes 2 and Weight Loss"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Mounjaro Tirzepatide<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"Tirzepatide\t\t\t\t\t\t\t\t\t\t\t
Tirzepatide for Weight Loss?<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Costa Rica Doctors Perform Hormone Pellet Implants in Men & Women<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Mounjaro Tirzepatide, better than Wegovy?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Tirzepatide is new drug recently approved by the FDA in May 2022 for the treatment of type 2 diabetes. It is a combination of two molecules: a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist and a dipeptidyl peptidase-4 (DPP-4) inhibitor. GLP-1 receptor agonists are a class of drugs that help to lower blood sugar levels by increasing insulin production and decreasing the amount of sugar produced by the liver. DPP-4 inhibitors work by preventing the breakdown of GLP-1, a hormone that helps to regulate blood sugar levels. Tirzepatide is currently approved for diabetes treatment, but may soon be in clinical trials for weight loss.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Tirzepatide was developed for the treatment of type 2 diabetes, and it is not specifically marketed as a weight loss medication.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

However, tirzepatide may cause weight loss as a side effect, as some studies have shown that GLP-1 receptor agonists may lead to modest weight loss in people with type 2 diabetes.<\/span><\/p>

GLP-1 receptor agonists work by increasing insulin production and decreasing the amount of sugar produced by the liver, which can help to lower blood sugar levels. They may also cause weight loss by decreasing appetite and increasing feelings of fullness. However, the exact mechanism by which GLP-1 receptor agonists cause weight loss is not fully understood and may be due to a combination of factors.<\/span><\/p>

It is important to note that tirzepatide is a newly approved diabetes drug and has not yet been approved for use by regulatory agencies for weight loss. As such, it is not currently available for use and its potential effects on weight loss are not fully known. If you are interested in using medication for weight loss, it is important to speak with a healthcare provider to determine the best course of treatment for you.<\/span><\/p>

When was Tirzepatide Approved by the FDA?<\/h3>

In May of 2022, The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection. The drug is manufactured by Eli Lilly. it is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. Both are considered incretin hormones. Its purpose is to improve glycemic control in adults with type 2 diabetes.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

FDA Fast Tracks Tirzepatide for Obesity Patients<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Lilly announced on Oct. 6 that the FDA granted tirzepatide a \u201cfast track\u201d review to be designated as a treatment for obesity. It’s expected that Tirzepatide could be approved as an obesity medication by 2023, and likely some doctors internationally will begin prescribing it before its approval date.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What are incretin hormones?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Incretin hormones are hormones produced in the gut that stimulate the release of insulin in response to food intake. They also inhibit the production of glucagon, a hormone that stimulates the liver to produce and release glucose into the bloodstream. Incretin hormones play a key role in glucose homeostasis and blood sugar control.<\/p>

There are two main types of incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is produced by L cells in the small intestine and colon, while GIP is produced by K cells in the small intestine. Both hormones are released in response to food intake, particularly the intake of carbohydrates.<\/p>

GLP-1 and GIP have a number of effects on the body, including:<\/p>